ZURA, KYG989201089

Zura Bio stock extends strong 12-month rally amid biotech momentum

Published on 09/22/2026 at 00:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zura Bio stock has gained 230.3% over the past 12 months as of September 20, 2026, highlighting strong momentum in the biotechnology sector. The shares are supported by a market capitalization of about USD 427 million and a focus on healthcare innovation.

ZURA, KYG989201089, Illustration mit AI erstellt.

Zura Bio stock has delivered a striking 230.3% price gain over the past 12 months, with the company’s market capitalization reaching about USD 427 million as of September 20, 2026, underscoring strong momentum in the biotechnology space.

Biotech performance puts Zura Bio in focus

According to AltIndex in a comparison updated on September 20, 2026, Zura Bio’s price stood at USD 4.49, with a 12-month change of plus 230.3% and a market capitalization of approximately USD 427 million.

The same comparison shows that while another biotech peer AVIR gained 10.8% in market cap over the past year, Zura Bio’s 230.3% price increase clearly outpaced that, highlighting how the stock has significantly outperformed at least one sector peer over the 12-month period.

Zura Bio’s market profile and recent trajectory

In the AltIndex overview, Zura Bio is categorized within the biotechnology industry and healthcare segment, reinforcing its positioning as a specialist in healthcare-related innovation and therapeutics.

The 12-month performance data, with Zura Bio’s price at USD 4.49 and a 230.3% increase, suggests that investors have revalued the company sharply higher over the past year, pushing its market capitalization to about USD 427 million as of September 20, 2026.

Stock level context for investors

Based on the AltIndex comparison as of September 20, 2026, Zura Bio’s reference price of USD 4.49 on its primary US listing and the associated 230.3% 12-month gain provide a key benchmark for investors evaluating the stock’s recent trajectory and relative performance in the biotechnology sector.